Transcription factor homeobox C9 (HOXC9) was identified as upregulated in colorectal cancer (CRC) by differential expression analysis of the GSE25070 dataset. The investigators report that higher HOXC9 expression predicted a poor prognosis in CRC. The abstract indicates an association between elevated HOXC9 levels and adverse clinical outcomes, establishing the rationale to examine HOXC9's functional role in tumor biology and anti-tumor immunity.
The study combined bioinformatic, in vitro, ex vivo immune co-culture, molecular, and in vivo approaches. Key elements described in the abstract include differential analysis of public expression data (GSE25070), measurement of mRNA and protein levels by qPCR and Western blot, and functional assays in CRC cell lines (LoVo and Caco2) including colony formation, transwell migration/invasion, and tumor-sphere formation to assess proliferation, motility, and stemness.
Immune-related experiments involved flow cytometric detection of surface programmed death ligand 1 (PD-L1) and co-culture of CRC cells with CD8+ T cells, followed by flow cytometric apoptosis assessment and qPCR quantification of immune-related transcripts. Mechanistic interaction between HOXC9 and neuropilin 1 (NRP1) was examined using chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. In vivo effects were tested using xenograft tumor assays. The abstract does not report detailed experimental parameters, sample sizes, or statistical metrics.
Silencing of HOXC9 in LoVo and Caco2 CRC cell models produced multiple anti-malignant effects. Specifically, HOXC9 knockdown suppressed cell proliferation as assessed by colony formation assays, and reduced cell migration and invasion in transwell assays. Tumor-sphere formation assays indicated decreased cell stemness following HOXC9 depletion. These findings together indicate that HOXC9 promotes core malignant behaviors in CRC cell lines.
HOXC9 knockdown decreased surface expression of PD-L1 on CRC cells, as detected by flow cytometry. In co-culture experiments with CD8+ T cells, CRC cells with reduced HOXC9 expression showed increased susceptibility to CD8+ T cell–mediated apoptosis, and altered immune-related mRNA levels were detected by qPCR in the co-culture system. Collectively, these results reported in the abstract indicate that HOXC9 contributes to immune evasion in CRC by supporting PD-L1 expression and suppressing CD8+ T cell anti-tumor function.
The abstract states that HOXC9 knockdown reduced CRC tumor growth in xenograft models and lowered tumor PD-L1 expression in vivo. These in vivo observations are presented as consistent with the in vitro and ex vivo immune findings, supporting a role for HOXC9 in promoting tumor progression and immune escape. Specific xenograft model details, such as mouse strain, number of animals, or tumor measurement statistics, are not provided in the abstract.
Mechanistic assays showed that HOXC9 elevates expression of neuropilin 1 (NRP1) via transcriptional activation. The interaction between HOXC9 and the NRP1 promoter was validated using chromatin immunoprecipitation (ChIP) and a dual-luciferase reporter assay, indicating direct regulatory control at the transcriptional level. This HOXC9 → NRP1 regulatory relationship is presented as the molecular basis linking HOXC9 activity to downstream effects on malignancy and immune modulation.
Functional rescue experiments reported in the abstract demonstrated that overexpression of NRP1 could reverse the inhibitory effects on malignant phenotypes and the enhanced immune function induced by HOXC9 downregulation. In other words, restoring NRP1 expression in HOXC9-silenced cells recovered proliferation, migration/invasion, stemness features, and immune-evasive properties including PD-L1–related effects. This epistatic evidence supports NRP1 as a critical downstream effector of HOXC9 in CRC.
The study identifies a HOXC9–NRP1 axis that contributes to CRC malignant progression and immune evasion, highlighting potential targets for therapeutic intervention aimed at tumor growth and immune resistance. The findings link transcriptional regulation by HOXC9 to NRP1 upregulation, PD-L1 expression, and suppression of CD8+ T cell anti-tumor activity.
Limitations based on the abstract: the report does not include numerical results, cohort sizes, detailed statistical analyses, or full experimental protocols. Translational implications and potential therapeutic strategies are implied but specific clinical validation, patient cohort data, or safety assessments were not reported in the abstract. For a complete assessment of methodology, effect sizes, and reproducibility, readers should consult the full text of the article.
Overall, the abstract presents consistent in vitro, ex vivo, and in vivo evidence that HOXC9 promotes colorectal cancer progression and immune evasion by transcriptionally activating NRP1, with downstream effects on PD-L1 expression and CD8+ T cell function.